193 related articles for article (PubMed ID: 33896035)
1. Analyzing the clinical outcomes of switching from cyclosporine to tacrolimus in pediatric hematopoietic stem cell transplantation.
Yalcin K; Celen S; Zhumatayev S; Daloglu H; Pashayev D; Öztürkmen S; Uygun V; Karasu G; Yesilipek A
Clin Transplant; 2021 Jul; 35(7):e14328. PubMed ID: 33896035
[TBL] [Abstract][Full Text] [Related]
2. Comparison of tacrolimus vs. cyclosporine in pediatric hematopoietic stem cell transplantation for thalassemia.
Zhumatayev S; Yalcin K; Celen SS; Karaman I; Daloglu H; Ozturkmen S; Uygun V; Karasu G; Yesilipek A
Pediatr Transplant; 2024 Feb; 28(1):e14688. PubMed ID: 38317344
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.
Furlong T; Storb R; Anasetti C; Appelbaum FR; Deeg HJ; Doney K; Martin P; Sullivan K; Witherspoon R; Nash RA
Bone Marrow Transplant; 2000 Nov; 26(9):985-91. PubMed ID: 11100278
[TBL] [Abstract][Full Text] [Related]
4. High incidence of severe cyclosporine neurotoxicity in children affected by haemoglobinopaties undergoing myeloablative haematopoietic stem cell transplantation: early diagnosis and prompt intervention ameliorates neurological outcome.
Noè A; Cappelli B; Biffi A; Chiesa R; Frugnoli I; Biral E; Finizio V; Baldoli C; Vezzulli P; Minicucci F; Fanelli G; Fiori R; Ciceri F; Roncarolo MG; Marktel S
Ital J Pediatr; 2010 Feb; 36():14. PubMed ID: 20181110
[TBL] [Abstract][Full Text] [Related]
5. [Mycophenolate mofetil in treatment of graft-versus-host disease after allogeneic hematopoietic cell transplantation: analysis of 44 cases].
Chen H; Liu KY; Liu DH; Xu LP; Han W; Chen YH; Huang XJ
Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(30):2127-30. PubMed ID: 19080474
[TBL] [Abstract][Full Text] [Related]
6. Effects of immunosuppressive agents on magnesium metabolism early after allogeneic hematopoietic stem cell transplantation.
Aisa Y; Mori T; Nakazato T; Shimizu T; Yamazaki R; Ikeda Y; Okamoto S
Transplantation; 2005 Oct; 80(8):1046-50. PubMed ID: 16278584
[TBL] [Abstract][Full Text] [Related]
7. Comparison of continuous and twice-daily infusions of cyclosporine A for graft-versus-host-disease prophylaxis in pediatric hematopoietic stem cell transplantation.
Umeda K; Adachi S; Tanaka S; Ogawa A; Hatakeyama N; Kudo K; Sakata N; Igarashi S; Ohshima K; Hyakuna N; Chin M; Goto H; Takahashi Y; Azuma E; Koh K; Sawada A; Kato K; Inoue M; Atsuta Y; Takami A; Murata M;
Pediatr Blood Cancer; 2015 Feb; 62(2):291-298. PubMed ID: 25307105
[TBL] [Abstract][Full Text] [Related]
8. Neurologic Complications of the Central Nervous System after Allogeneic Stem Cell Transplantation: The Role of Transplantation-Associated Thrombotic Microangiopathy as a Potential Underreported Cause.
Sala E; Neagoie AM; Lewerenz J; Saadati M; Benner A; Gantner A; Wais V; Döhner H; Bunjes D
Transplant Cell Ther; 2024 Jun; 30(6):586.e1-586.e11. PubMed ID: 38508452
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Tacrolimus and Cyclosporine Combined With Methotrexate for Graft Versus Host Disease Prophylaxis After Allogeneic Hematopoietic Cell Transplantation.
Huang B; Lin X; Zhang Z; Zhang Y; Zheng Z; Zhong C; He X; Chen M
Transplantation; 2020 Feb; 104(2):428-436. PubMed ID: 31283681
[TBL] [Abstract][Full Text] [Related]
10. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
Kharfan-Dabaja M; Mhaskar R; Reljic T; Pidala J; Perkins JB; Djulbegovic B; Kumar A
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010280. PubMed ID: 25061777
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporine levels > 195 μg/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Bianchi M; Heim D; Lengerke C; Halter J; Gerull S; Kleber M; Tsakiris DA; Passweg J; Tzankov A; Medinger M
Ann Hematol; 2019 Apr; 98(4):971-977. PubMed ID: 30542943
[TBL] [Abstract][Full Text] [Related]
12. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
[TBL] [Abstract][Full Text] [Related]
13. Favorable outcomes of tacrolimus compared with cyclosporine A for GVHD prophylaxis in HSCT for standard-risk hematological diseases.
Nasu R; Nannya Y; Shinohara A; Ichikawa M; Kurokawa M
Ann Hematol; 2014 Jul; 93(7):1215-23. PubMed ID: 24590535
[TBL] [Abstract][Full Text] [Related]
14. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
15. [Comparative study on the efficacy and safety of continuous versus twice-daily 3-hour infusion of cyclosporine A in pediatric hematopoietic stem cell transplantation].
Nodomi S; Umeda K; Matsubara H; Daifu T; Kato I; Hiramatsu H; Watanabe K; Heike T; Adachi S
Rinsho Ketsueki; 2012 Nov; 53(11):1891-7. PubMed ID: 23257669
[TBL] [Abstract][Full Text] [Related]
16. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R
Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine A-related neurotoxicity after haploidentical hematopoietic stem cell transplantation in children with hematopathy.
Wang Y; Zheng Y; Wen J; Ren J; Yuan X; Yang T; Hu J
Ital J Pediatr; 2021 Apr; 47(1):83. PubMed ID: 33794964
[TBL] [Abstract][Full Text] [Related]
18. Impact of cyclosporine-A concentration in T-cell replete haploidentical allogeneic stem cell transplantation.
Yang X; Yang S; Sun A; Qiu H; Tang X; Han Y; Wu D
Clin Transplant; 2018 Apr; 32(4):e13220. PubMed ID: 29493007
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic comparison of cyclosporin A and tacrolimus in graft-versus-host disease prophylaxis.
Moiseev IS; Burmina EA; Muslimov AR; Pirogova OV; Bondarenko SN; Darskaya EI; Tarakanova YA; Senina NG; Afanasyev BV
Ann Hematol; 2017 Jun; 96(6):935-942. PubMed ID: 28343273
[TBL] [Abstract][Full Text] [Related]
20. Achievement of target cyclosporine concentrations as a predictor of severe acute graft versus host disease in children undergoing hematopoietic stem cell transplantation and receiving cyclosporine and methotrexate prophylaxis.
Punnett A; Sung L; Price V; Das P; Diezi M; Doyle J; Dupuis LL
Ther Drug Monit; 2007 Dec; 29(6):750-7. PubMed ID: 18043472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]